Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a hold rating to a buy rating in a research report released on Friday morning.

Several other equities analysts have also weighed in on the company. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. UBS Group cut their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Bank of America decreased their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Finally, Piper Sandler boosted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Down 6.9 %

Shares of TEVA stock opened at $13.83 on Friday. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a market cap of $15.68 billion, a P/E ratio of -9.54, a P/E/G ratio of 1.44 and a beta of 0.82. The stock has a 50 day moving average of $16.52 and a 200 day moving average of $18.01. Teva Pharmaceutical Industries has a twelve month low of $12.51 and a twelve month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, sell-side analysts expect that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc lifted its stake in shares of Teva Pharmaceutical Industries by 437.8% in the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company’s stock worth $81,000 after buying an additional 4,312 shares in the last quarter. Central Pacific Bank Trust Division raised its holdings in Teva Pharmaceutical Industries by 25.0% in the 1st quarter. Central Pacific Bank Trust Division now owns 53,030 shares of the company’s stock valued at $815,000 after acquiring an additional 10,603 shares during the last quarter. Wellington Management Group LLP lifted its stake in Teva Pharmaceutical Industries by 2.1% in the 4th quarter. Wellington Management Group LLP now owns 185,912 shares of the company’s stock worth $4,098,000 after purchasing an additional 3,816 shares in the last quarter. Centaurus Financial Inc. boosted its holdings in shares of Teva Pharmaceutical Industries by 97.2% during the 4th quarter. Centaurus Financial Inc. now owns 35,279 shares of the company’s stock worth $778,000 after purchasing an additional 17,388 shares during the last quarter. Finally, Siemens Fonds Invest GmbH purchased a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $611,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.